Objective: In cases of cervical carcinogenesis the gradient from low to high-grade lesions is characterized by increasing nuclear atypia and the failure of cellular differentiation. These phenotypic changes are presumed to be accompanied by increased genetic instability that can be documented using the micronucleus (MN) assay in exfoliated cervical cells.
Introduction
It is true that cervical carcinoma owes the most gratifying success story in the history of oncology till date. Credit goes to its long preinvasive phase, easy
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Deeksha Pandey 1 and applicable screening methods, and effective treatment of preinvasive lesions. After the popularization of Pap test as a screening method for cervical carcinoma in 1960s the incidence of frank carcinoma cervix as well as mortality because of it, has definitely dropped down. Overall, populationbased cervical screening programmes led to a decrease in cervical cancer incidence in developed countries with an estimated 60% compared to that of 1960 [1] [2] [3] [4] . Despite this cervical cancer remains the second most common cancer among women worldwide. About 500,000 women are diagnosed with cervical cancer contributing to around 270,000 deaths, across the globe every year. Out of these, the burden of 230,000 (85%) deaths is owned only by developing countries, with bare minimal resources to cope up with the situation 5 . In India alone there are an estimated 132,000 new cases and 74,000 deaths each year 6 . Ineffectiveness of Pap test in controlling cervical cancer specially in the developing part of the world, can be explained because of the subjectivity of the test as well as a high false positivity and false negativity rate, both of at least 20% 7, 8 . A recent overview of European and North American studies revealed that the sensitivity of cytology for high-grade preinvasive lesions and cervical cancer is on average not higher than about 55% 9 .
In cases of cervical carcinogenesis the gradient from low to high-grade lesions is characterized by increasing nuclear atypia and the failure of cellular differentiation. These phenotypic changes are presumed to be accompanied by increased genetic instability that can be documented using the micronucleus (MN) assay in exfoliated cervical cells 10 .
Micronuclei are fragments or whole chromosomes, which did not reach spindle poles during mitosis and remained encapsulated at telophase in a separate nucleus 11 . Over the last decade, the wide applicability of the micronucleus test in peripheral blood lymphocytes and the simplicity of scoring have made it an attractive cytogenetic tool to assess occupational and environmental exposures to genotoxic agents. The formation of micronuclei is considered to be an effective biomarker of diseases associated with DNA damage 12 . The micronuclei testing in the exfoliated samples is a cost effective, non-invasive method which can be a useful biomarker for the detection of human cancer risk in organs from where exfoliated cells can be obtained 13 .
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We hypothesize that a simple procedure of counting micronuclei in a cytology smear can be used to stratify the preinvasive disease of the uterine cervix. This method in conjunction with present cytology based test will be a helpful tool for triage, follow up or treatment in cases of borderline picture or doubtful cases. Methodology: Exfoliated cytology samples were collected during routine Pap smear testing or during per-speculam examination, before biopsy in cases of frank carcinoma, with the help of a sterile cyto-brush. Samples were collected in a 15 ml sterile plastic tube, half filled with phosphate buffer solution (PBS). Samples were then transferred to the lab in the same medium as soon as possible after collection. These samples were then centrifuged at 4000 rpm for 10 minutes. The supernatant was thrown carefully. The cell pellet was then dissolved in 2 to 5 ml of PBS depending upon the size of the cell pellet, with gentle shaking movements. A thin smear was prepared from each sample on a glass slide, which was then stained with acridine orange (a DNA specific dye). Around thousand cells per slide (whenever possible) were counted under fluorescent microscope, 20-40 X magnification and the number of micro-nucleated cells, total number of micronuclei were recorded down. Only cells containing intact nuclei that were not clumped, smeared or overlapped were included in the analysis. Cells with degenerative processes and so called nuclear anomalies, such as karyorrhexis, karyolysis, pycnosis, condensed chromatin were not considered. Questionable micronuclei were disregarded. Number of binucleates and trinucleates was also counted. All these patients were followed up with colposcopy and directed biopsy (whenever required). In cases of frank carcinoma histopathology was taken into consideration. Results were compared with the gold-standard histopathology report, in cases of frank growth on the cervix or whenever a colposcopy directed biopsy was performed. In the remaining cases the cytology report was taken in account for comparison of results.
Material and methods

Statistical analysis:
Statistical calculations were performed in SPSS 11.5. As the data were not normally distributed among the population studied, non parametric Kruskal Wallis test was used. For calculating the P value (test of significance) MannWhitney U test was applied.
Results
A) Demographic characteristics of the population studied (age and parity):
Age distribution among the five groups studied (normal smears, LSIL, HSIL, cervical carcinoma fresh cases without treatment and cervical carcinoma patients on chemo-radiation (CR)) is not normally distributed. Menopausal status, smoking, and oral contraceptive use are the important risk factors known to be associated with cervical carcinoma. In the population we studied 70-100% women had attained menopause in the HSIL and cancer groups as compared to 27% and 33% in the normal and LSIL groups respectively. The incidence of smoking was more or less same. The high incidence of smoking among the HSIL group can be ignored because of the very small sample size in that particular group. Interestingly in the population studied the median incidence of oral contraceptive pill (OCP) use was lower in the carcinoma groups compared to the normal and LSIL groups ( Table 2 ).
C) Relationship of MN assay and other numeric nuclear abnormalities with cervical lesions: Table 3 summarizes the values of various parameters used in MN assay per slide in all samples included in the study, irrespective of the cell count. It is evident that the micro-nucleated cells as well as the total number of micronuclei show increasing trend towards malignization. One interesting point to be appreciated is that as contrary to our initial belief that chemo-radiation will cause more DNA damage thus leading to higher number of micronuclei formation; we noted more or less similar counts in both the situations (fresh carcinoma and carcinoma on CR).
D) MN Ratios:
As it has been reported earlier 31 that the results of MN assay are more reliable and reproducible if the total number of cells counted per sample is more than 1000. But practically it was not possible to count 1000 or more samples in each and every slide. So, we made the calculations again, this time excluding those 50 samples, where we could not count 1000 or more cells. But still we did not get any extra beneficial result of doing that, as still we could not establish a significant difference between any variable of MN assay in group 2 and group 3. So we went one step ahead and with the help of the following formula tried to recalculate the ratios, so as to minimize the bias and increase reproducibility:
Micro Having found out that in the MN assay the first two variables, namely micro-nucleated cells and the total number of micro-nuclei have significantly different values for normal as compared to at risk group and cancer group, with no significant difference between high risk group and cancer group, we tried to obtain a cut off using the ROC curve. This cut off can be used to differentiate between no disease group (normal + LSIL) and disease group (HSIL + carcinoma).
As seen in Figure 3 , the area under the curve (AUC) tells that micro-nucleated cell ratio is an excellent test, with AUC in the range of 0.90 to 1.00 to differentiate between the disease (HSIL + carcinoma) and no disease (normal + LSIL) groups. As the idea is to use this test for screening purpose the best cut off will be 0.1999. At this cut off we can achieve the sensitivity as high as 91.4% with a specificity of 82.8%. Similarly by ROC curve obtained from the micronuclei ratio confers that this test also is an excellent test with AUC of 0.936. 91.4% sensitivity and 82.8% specificity can be obtained by keeping the cut off at 0.1999.
The advantage of combining both the ratios together does not confer any additional benefit in terms of sensitivity and specificity. So, either of the test alone can be used.
Discussion
Present study shows that either of the two independent variables used in MN assay 1) micronucleated cell ratio and 2) total number of micro-nuclei ratio can be used to obtain a high sensitivity and specificity to discriminate between no disease (normal + LSIL) patients and disease (HSIL + carcinoma) patients.
Since HPV infection induces cytogenetic instability in cervix cells, it can be evaluated by means of MN assay. Recently Cortes Gutierrez EI et al demonstrated an association between HPV type infection and higher MN frequencies 14 . Indeed, it has been shown that in exfoliated cervical cells of patients with moderate and severe dysplasia a significantly higher frequency of MN level compared with healthy women 15 . The same effect was shown by a group of Mexican investigators significantly increased MN frequency in cervix cells of women with invasive cancer, and low-and high-grade squamous intraepithelial lesions (LSIL, HSIL) 16 . A correlation between MN frequency and grade of cervical lesion, and a positive linear trend between the MN frequency and increased cervical cancer risk was also shown 16 .
Moreover, a retrospective study was performed to investigate the frequency of cells with MN in Pap smears from patients, and a strong correlation was observed between these two parameters -MN frequency and grade of cervical lesions 10 . Gandhi and Kaur found a correlation between the stages of cancer and MN number in exfoliated cervical cells [17] [18] [19] . Samanta et al. demonstrated that MN score may be helpful in identifying the true CIN cases that are mislabeled as ASCUS on cervical smear and concluded that in future, MN score can be used as an additional biomarker in cervical cancer screening 20 .
Micronucleus assay could be used to assess chromosome damage as they are examined in routine cytopathological preparations 21 . Their frequency of occurrence is a measure of chromosome breakage in early cell divisions and the number of MN is known to increase with carcinogenic stimuli, long before development of clinical symptoms 21 . The advantage of MN assay lies in the fact that it is very simple, as the scoring of MN does not take much time or expertise 21 .
Based on the mentioned data, some investigators 10, 17, 18, 19, 20, 22 proposed that MN test in exfoliated cervix and urothelial cells should be applied in massscreening programmes in developing countries based on high correlation between the results in MN assay in exfoliated cervix cells and Pap test on one hand, and a correlation between cancer and increased MN level in urothelial and cervix cells on the other. It may be possible to evaluate the frequency of MN in exfoliated cervical cells in order to obtain additional criterion for establishing cervical cancer risk. The variations in MN frequency in different stages of cancer from low grade to high grade invasive stage may follow a specific pattern, allowing for a Цитология и classification system to be made, so as to increase the sensitivity and specificity of cervical cytology. This could impact in diagnostics and secondary prevention of cervical cancer.
The available literature on MN count and cervical cancer has already shown a positive correlation between MN level and progression towards cervical cancer (Table 4) .
Till date studies have shown a positive correlation of MN with progressive phases of premalignant cervical lesions. However, we are the first to calculate the sensitivity and specificity of this test if it is to be used as a screening tool.
The study, however has many limitations and so the results should be interpreted carefully. The most important limitation is the small sample size of premalignant lesions (LSIL and HSIL). As Nersesyan et al concluded in their mini review that to obtain reliable results no less than 1000, but better 2000 cells ought to be studied 23 we kept our strategy to keep the number of cells counted to be 1000 plus, but as many of the slides showed less cellularity we included those slides also in our final analysis where we could count cells in the range of 500-999. In this study, however we could not find advantage of counting only more than 1000 cells. When we took into account all samples irrespective of the cell count, we could establish significant difference between the no disease and the disease group. Even after excluding the slides with cell count of less than 1000 (500-999) the results did not change. But to overcome the bias and increase the reproducibility we went ahead with calculating the ratios (individual variable/ total number of the cells counted), which seems to be more relevant and practical measure. Although, further larger studies are required to prove our result, still it forms a platform for future studies co-relating individual variables of MN assay with progression of cervical carcinogenesis. 
Conclusion
Our study shows that MN counting can be a helpful screening tool in conjunction with conventional Pap test for screening of cervical cancer till we are awaiting validation of better molecular or genetic (epigenetic) biomarkers, in years to come. 
